Observational studyAIDS (London, England)2016
A longitudinal, HIV care continuum: 10-year restricted mean time in each care continuum stage after enrollment in care, by history of IDU.
Observational study in AIDS (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review.BMC public health · 2021Pooled it
- A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.Lancet (London, England) · 2018Trial
- Pooled Multinomial Logistic Regression for Parametric G-computation in the Presence of Competing Events.Epidemiology (Cambridge, Mass.) · 2026Article
- Feasibility and Preliminary Effectiveness of a Data-to-Care Intervention for HIV-Positive People Who Inject Drugs in Ukraine: A Pilot Cluster-Randomized Trial.AIDS and behavior · 2026Article
- Patterns in Mental Health Symptoms, Substance Use, and Viral Suppression in People with HIV: A Clustering Analysis.AIDS and behavior · 2025Article
- Transitions through the HIV continuum of care in people enrolling in care with advanced HIV disease in Latin America.IJID regions · 2025Article
- Depression and the revolving door of HIV care: using multistate approaches to understand complex longitudinal exposure/outcome relationships among a cohort of people entering HIV care in Cameroon from 2019 to 2020.BMJ public health · 2025Article
- Retention in care and antiretroviral therapy adherence among Medicaid beneficiaries with HIV, 2001-2015.AIDS care · 2024Article
- Retention in care and antiretroviral therapy adherence among Medicaid beneficiaries with HIV, 2001-2015.medRxiv : the preprint server for health sciences · 2024Article
- Longitudinal patterns of use of stimulants and opioids in the AIDS linked to the IntraVenous experience cohort, 2005-2019.The International journal on drug policy · 2024Article
- Evaluating the agreement between different substance use recall periods in multiple HIV cohorts.Drug and alcohol dependence · 2024Article
- Statistical methods applied for the assessment of the HIV cascade and continuum of care: a systematic scoping review.BMJ open · 2023Article
- Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014-2019.Addiction (Abingdon, England) · 2023Article
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.Addiction science & clinical practice · 2023Article
- Alcohol use and the longitudinal HIV care continuum for people with HIV who enrolled in care between 2011 and 2019.Annals of epidemiology · 2023Article
- Alcohol Use Disorder and Recent Alcohol Use and HIV Viral Non-Suppression Among People Engaged in HIV Care in an Urban Clinic, 2014-2018.AIDS and behavior · 2022Article
- The Effect of Buprenorphine on Human Immunodeficiency Virus Viral Suppression.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Novel Longitudinal Methods for Assessing Retention in Care: a Synthetic Review.Current HIV/AIDS reports · 2021Review
- Disparities in Care Outcomes in Atlanta Between Black and White Men Who Have Sex With Men Living With HIV: Protocol for a Prospective Cohort Study (Engage[men]t).JMIR research protocols · 2021Article
- Longitudinal Care Cascade Outcomes Among People Eligible for Antiretroviral Therapy Who Are Newly Linking to Care in Zambia: A Multistate Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesWe present a novel, patient-centric, longitudinal summary of patient progress through the HIV care continuum. Using this new approach, we compare person-time spent alive, in care, on antiretroviral therapy (ART), and virally suppressed among people who inject drugs (PWID) and those who do not (non-IDU).
designProspective clinical observational cohort study.
methodsWe followed ART-naive patients with detectable HIV viral loads who enrolled in the Johns Hopkins HIV Clinical Cohort from enrollment until the occurrence of several care continuum-related milestones, including ART initiation and viral suppression, and until several care continuum-related failures, including loss to clinic and death. We added and subtracted cumulative incidence curves to estimate the proportion of the cohort in each of seven continuum stages across the 10 years following enrollment in clinical care.
resultsPWID composed 32% of the study sample (n = 1443). Over 10 years following enrollment in care, PWID and non-IDU spent only 23 and 37%, respectively, of person-time in care, on ART, and virally suppressed. PWID lost 8.9 more months of life compared with non-IDU and spent an additional 5.0 months on ART but not virally suppressed, and an additional 5.5 months in care but not on ART. There were not meaningful improvements in the 5-year restricted mean person-time differences comparing PWID to non-IDU across enrollment cohorts (2000-2003, 2004-2007, 2008-2014).
conclusionEfforts to increase viral suppression among PWID should focus on increasing ART initiation and improving adherence to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.